Benserazide
Research News and Information

Monday, November 23, 2009

Kinetic characterization of the oxidation of carbidopa and benserazide by tyrosinase and peroxidase.

5 Jun 2009 Carbidopa and benserazide have been described as inhibitors of dopa decarboxylase and both have been used in the treatment of Parkinson's disease. Because of their chemical structure as polyphenols, these compounds can behave as substrates of ... Read more...

L-dopa modulates functional connectivity in striatal cognitive and motor networks: a double-blind placebo-controlled study.

Jun 2009 Functional connectivity (FC) analyses of resting-state fMRI data allow for the mapping of large-scale functional networks, and provide a novel means of examining the impact of dopaminergic challenge. Here, using a double-blind, placebo-controlled ... Read more...

Pharmacokinetic profile of talipexole in healthy volunteers is not altered when it is co-administered with Madopar (co-beneldopa).

30 May 2009 OBJECTIVES: To investigate the pharmacokinetics of talipexole hydrochloride tablets and the potential influence of Madopar (benserazide and levodopa combination; co-beneldopa) tablets on talipexole's pharmacokinetics when the two tablets are ... Read more...

Latest indexed articles for 'Benserazide'

These are the very latest articles for this heading:

• Kinetic characterization of the oxidation of carbidopa and benserazide by tyrosinase and peroxidase. 5 Jun 2009
• L-dopa modulates functional connectivity in striatal cognitive and motor networks: a double-blind placebo-controlled study. Jun 2009
• Pharmacokinetic profile of talipexole in healthy volunteers is not altered when it is co-administered with Madopar (co-beneldopa). 30 May 2009
• Striatal overexpression of DeltaJunD resets L-DOPA-induced dyskinesia in a primate model of Parkinson disease. 26 May 2009
• Catecholamine excess in a patient with restless legs syndrome treated with levodopa and benserazide. 29 Apr 2009
• Reversible Pisa syndrome in patients with Parkinson's disease on dopaminergic therapy. 16 Mar 2009
• Local administration of sarizotan into the subthalamic nucleus attenuates levodopa-induced dyskinesias in 6-OHDA-lesioned rats. 20 Jan 2009
• Quality of life in early Parkinson's disease treated with levodopa/carbidopa/entacapone. 13 Jan 2009
• Severe gastroparesis in a patient with advanced Parkinson's disease. 30 Dec 2008
• Comparison of intrastriatal administration of noradrenaline and l-DOPA on dyskinetic movements: a bilateral reverse in vivo microdialysis study in 6-hydroxydopamine-lesioned rats. 22 Dec 2008
• Fifty cases of Parkinson's disease treated by acupuncture combined with madopar. 29 Nov 2008
• Acute stepwise challenge test with levodopa in treated patients with parkinsonism. 12 Nov 2008
• Alpha1-adrenoceptors mediate dihydroxyphenylalanine-induced activity in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaques. 25 Oct 2008
• Implication of NMDA receptors in the antidyskinetic activity of cabergoline, CI-1041, and Ro 61-8048 in MPTP monkeys with levodopa-induced dyskinesias. 12 Aug 2008
• Simultaneous chemiluminometric determination of levodopa and benserazide in a multi-pumping flow system with multivariate calibration. 30 Jul 2008
• Influences of levodopa on adipose tissue and skeletal muscle metabolism in patients with idiopathic Parkinson's disease. 28 Jul 2008
• Molecular analyses of GCH-1, TH and parkin genes in Chinese dopa-responsive dystonia families. 9 Jun 2008
• Paradoxical effects of adenosine receptor ligands on hydroxyl radical generation by L-DOPA in the rat striatum. 29 Apr 2008
• Impact of endurance exercise on levodopa-associated cortisol release and force increase in patients with Parkinson's disease. 10 Mar 2008
• [Isolated pulmonary hypertension and pergolide] 12 Feb 2008

See a longer list of these articles.

Technical information about 'Benserazide'

Definition: An inhibitor of DOPA DECARBOXYLASE that does not enter the central nervous system. It is often given with LEVODOPA in the treatment of parkinsonism to prevent the conversion of levodopa to dopamine in the periphery, thereby increasing the amount that reaches the central nervous system and reducing the required dose. It has no antiparkinson actions when given alone.

Chemical name: DL-Serine, 2-((2,3,4-trihydroxyphenyl)methyl)hydrazide

Registry Number: 322-35-0

Descriptor UI: D001545

Alternative terms: Benserazide; Seryltrihydroxybenzylhydrazine; Seryltrihydroxy Benzylhydrazine; Benzylhydrazine, Seryltrihydroxy; DL-Serine 2-((2,3,4-trihydroxyphenyl)methyl)hydrazide; Serazide; Ro 4-4602; Ro 4 4602; Ro 44602;

Allowable Qualifiers: administration & dosage; adverse effects; analogs & derivatives; analysis; antagonists & inhibitors; blood; cerebrospinal fluid; chemical synthesis; classification; diagnostic use; economics; history; immunology; isolation & purification; metabolism; pharmacokinetics; pharmacology; poisoning; radiation effects; standards; supply & distribution; therapeutic use; toxicity; urine; chemistry; contraindications; agonists;

Pharmacological Action: Antiparkinson Agents; Enzyme Inhibitors; Dopamine Agents;

Tree Number: D02.442.175;

Online Note: use BENSERAZIDE to search SERYLTRIHYDROXY BENZYLHYDRAZINE 1973-78 (as Prov 73-74)

History Note: 91(79); was see under HYDRAZINES 1979-90; was SERYLTRIHYDROXY BENZYLHYDRAZINE see under HYDRAZINES 1973-78 (Prov 1973-74)